Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-TDP-43 antibody
Therapeutic Area: Neurology Product Name: Anti-TDP-43 antibody
Highest Development Status: Preclinical Product Type: Large molecule
Recipient: WuXi Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 09, 2020
Details:
The partnership focuses on developing AC Immune’s clinical antibody candidate to ensure it has high-affinity for TDP-43 and is capable of preventing the intercellular spread of toxic species.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Semorinemab
Therapeutic Area: Neurology Product Name: RG6100
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
In a Phase 2 trial of the anti-Tau antibody, semorinemab, in early (prodromal to mild) Alzheimer’s disease (AD) which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-TDP-43 antibody
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
Advancing the anti-TDP-43 antibody towards clinical development is the latest in a series of important milestones already achieved this year in the Company’s cutting-edge therapeutic and diagnostic programs targeting TDP-43 – which are amongst the most comprehensive in the field.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACI-35.030
Therapeutic Area: Neurology Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
The ACI-35.030 anti-pTau vaccine is the second vaccine under investigation generated from AC Immune’s SupraAntigen™ platform, along with ACI-24, a proprietary anti-amyloid beta (Abeta) vaccine currently in Phase 1b/Phase 2 clinical development in two separate indications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACI3024
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $105.1 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 23, 2020
Details:
The collaboration combines AC Immune’s proprietary Morphomer discovery platform technology and early development experience with Lilly’s clinical development expertise and commercial capabilities.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
